SARS-CoV-2 PLpro-IN-7 

SARS-CoV-2 PLpro-IN-7 (Compound 18) is a selective SARS-CoV-2 PLpro inhibitor with an IC₅₀ of 13.3 μM. SARS-CoV-2 PLpro-IN-7 exerts antiviral activity against SARS-CoV-2 (with an EC₅₀ of 11 μM for SARS-CoV-2 in Huh7.5 cells). SARS-CoV-2 PLpro-IN-7 is applicable to research related to COVID-19^[1].

SARS-CoV-2 PLpro-IN-7 (0.2-200 μM; 30 min) inhibits purified SARS-CoV-2 PLpro with an IC₅₀ of 13.3 ± 9 μM; after a 30-min pre-incubation, the inhibition rate reaches 80% at a concentration of 50 μM^[1].
SARS-CoV-2 PLpro-IN-7 (0.156-20 μM; 48 h) inhibits SARS-CoV-2 replication in Huh7.5 cells, with an EC₅₀ of 11 ± 2 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

541.56

C₂₉H₃₀F₃N₃O₄

CCOC(/C=C/CNC(CCNC(C=CC(C(F)(F)F)=C1)=C1C(N[C@H](C)C2=CC=CC3=C2C=CC=C3)=O)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Huang HY, et al. Integration of computational and experimental techniques for the discovery of PL^pro covalent inhibitors. When large virtual screening and rational design meet. Eur J Med Chem. 2026;308:118698.  [Content Brief]